EUCTR2016-004291-21-AT进行中（未招募）1 期
Effect of phosphodiesterase-5 inhibition with Tadalafil on SystEmic RightVEntricular size and function – a multi-center, double-blind, randomized,placebo-controlled clinical trial – SERVE Trial - SERVE
Insel Gruppe AG - Inselspital Universitätsklinik für Kardiologie0 个研究点目标入组 98 人开始时间: 2017年12月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 98
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Adults (=18 years) with a systemic RV due to due to D-TGA repaired with an atrial switch procedure or due to ccTGA
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 98
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •No informed consent; myocardial infarction, stroke, or open heart
- •surgery in the previous 3 months; expected heart
- •transplant within the next 6 months; pregnant or nursing women;
- •severe renal insufficiency; hypersensitivity to
- •Tadalafil; known allergy to iodinated or Gadolinium-based contrast
研究者
相似试验
已完成
3 期
Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and FunctionHeart Defects, CongenitalTransposition of Great Vessels With Ventricular InversionNCT03049540Insel Gruppe AG, University Hospital Bern100
进行中（未招募）
3 期
Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension (PASSION). A randomized, placebo-controlled, double-blind, parallel group, multi-center, phase III trialheart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertensionDRKS00014595Philipps-Universität Marburg125
进行中（未招募）
1 期
Study, to investigate, if Tadalafil, a Phosphodiesterase-5 inhibitor, is benficial for the treatment of pulmonary hypertension due to left heart failure.Combined post- and pre-capillary pulmonary hypertension and heart failure with preserved ejection fractionMedDRA version: 20.0Level: LLTClassification code 10077732Term: Pulmonary hypertension WHO functional class IISystem Organ Class: 100000004855MedDRA version: 20.0Level: LLTClassification code 10024106Term: Left heart failureSystem Organ Class: 100000004849EUCTR2017-003688-37-DEPhilipps-Universität Marburg372
进行中（未招募）
1 期
Phosphodiesterase-type 5 inhibitors in adult and adolescent patients with univentricular heart disease: a multi-center, randomized, double blind phase III studyEUCTR2018-004828-11-FRniversity Hospital of Montpellier50
Unknown
3 期
A clinical trial to study the effects of Tadalafil in patients with pulmonary hypertension.CTRI/2009/091/000744Division of Cardiology,Department of Medicine,Mahatma Gandhi Memorial Medical College and M.Y.Hospital,Indore,India60